 |
Parts of this article (those related to clinical trial phase III) need to be updated. Please help update this article to reflect recent events or newly available information. (September 2016)
|
 |
This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (June 2019)
|
Cevira is in development as a local treatment for Cervical intraepithelial neoplasia lesions and human papilloma virus (HPV) of the cervix without damaging healthy tissue. With Cevira, Photocure aims to develop the first non-surgical treatment for precancerous cervical lesions using photodynamic therapy (PDT). Cevira treatment is administered locally and remains in contact with the cervix to deliver treatment for up to 24 hours. A cup holds the ointment against the cervix for initial absorption. After a few hours, a light source within the cup emits light at a specific wavelength so the Active Pharmaceutical Ingredient, hexylaminolevulinate (HAL), reacts with the tissue.[1][2]
